935700 Stock Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Notes are coming soon
Gilead Sciences, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$79.01|
|52 Week High||US$82.53|
|52 Week Low||US$54.94|
|1 Month Change||0.053%|
|3 Month Change||15.59%|
|1 Year Change||5.34%|
|3 Year Change||31.67%|
|5 Year Change||3.95%|
|Change since IPO||-26.23%|
Recent News & Updates
|935700||CH Biotechs||CH Market|
Return vs Industry: 000935700 exceeded the Swiss Biotechs industry which returned -70.2% over the past year.
Return vs Market: 000935700 exceeded the Swiss Market which returned -11.1% over the past year.
|935700 Average Weekly Movement||n/a|
|Biotechs Industry Average Movement||7.0%|
|Market Average Movement||4.0%|
|10% most volatile stocks in CH Market||7.2%|
|10% least volatile stocks in CH Market||2.0%|
Stable Share Price: Insufficient data to determine 000935700's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine 000935700's volatility change over the past year.
About the Company
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.
Gilead Sciences, Inc. Fundamentals Summary
|935700 fundamental statistics|
Is 935700 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|935700 income statement (TTM)|
|Cost of Revenue||US$5.64b|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 02, 2023
|Earnings per share (EPS)||2.66|
|Net Profit Margin||12.29%|
How did 935700 perform over the long term?See historical performance and comparison